Ebixa dosing made easier

Ebixa (memantine) is now licensed for once-daily administration in the treatment of patients with moderate to severe Alzheimer's disease.

A new 20mg tablet has been added to the Ebixa range to simplify the once-daily administration and a new treatment initiation pack has been launched to aid titration.

View Ebixa drug record

Further information: Lundbeck

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

More from MIMS

New products - live tracker

New products - live tracker

EXCLUSIVE TO SUBSCRIBERS See the latest products added...

Drug price changes - live tracker

Drug price changes - live tracker

EXCLUSIVE TO SUBSCRIBERS Use our constantly updated...

Direct-acting oral anticoagulants set for wider use under NHS deal

Direct-acting oral anticoagulants set for wider use under NHS deal

More than half a million more people will be able to...

NICE recommends SGLT2 inhibitors for chronic kidney disease

NICE recommends SGLT2 inhibitors for chronic kidney disease

Updated NICE guidance on type II diabetes recommends...